The impact of quality-of-life data in relative effectiveness assessments of new anti-cancer drugs in European countries.
Qual Life Res
; 26(9): 2479-2488, 2017 09.
Article
em En
| MEDLINE
| ID: mdl-28401419
ABSTRACT
PURPOSE:
The aim of this study is to investigate the role of health-related quality-of-life (QoL) data in relative effectiveness assessments (REAs) of new anti-cancer drugs across European jurisdictions, during health technology assessment procedures.METHODS:
Comparative analysis of guidelines and publicly available REAs in six European jurisdictions of anti-cancer drugs approved by EMA between 2011 and 2013.RESULTS:
Fourteen anti-cancer drugs were included, adding up to 79 REAs. Whilst all guidelines state that QoL is a relevant endpoint to determine the relative effectiveness of new cancer drugs, QoL data were included in only 54% of the 79 reports and their impact on the recommendations was limited.CONCLUSIONS:
Whilst national guidelines recognize the relevance of QoL to determine the relative effectiveness of new anti-cancer drugs, this is not well-reflected in current assessments. Developing and implementing into REAs specific evidence requirements for QoL data would improve the use of this patient-centred outcome in future reimbursement and pricing decisions.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Qualidade de Vida
/
Neoplasias
/
Antineoplásicos
Tipo de estudo:
Health_technology_assessment
/
Observational_studies
/
Prevalence_studies
/
Risk_factors_studies
Limite:
Humans
País como assunto:
Europa
Idioma:
En
Ano de publicação:
2017
Tipo de documento:
Article